Concord Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE858L01010
  • NSEID:
  • BSEID: 538965
INR
68.51
-1.28 (-1.83%)
BSENSE

Nov 20

BSE+NSE Vol: 1.23 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Veerhealth Care
Vaishali Pharma
Parmax Pharma
Concord Drugs
Tyche Industries
Denis Chem Lab
Alpa Laboratorie
Mercury Labs
Pharmaids Pharma
Cian Healthcare
Amwill Health
Why is Concord Drugs Ltd ?
1
Weak Long Term Fundamental Strength with a 12.96% CAGR growth in Operating Profits over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.22 times
  • The company has been able to generate a Return on Equity (avg) of 3.13% signifying low profitability per unit of shareholders funds
2
Stock is technically in a Bearish range
  • The technical trend has deteriorated from Mildly Bearish on 19-Nov-26 and has generated -1.99% returns since then
  • Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
3
Underperformed the market in the last 1 year
  • Even though the market (BSE500) has generated returns of 0.37% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -15.78% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Concord Drugs for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Concord Drugs
-15.78%
-0.37
42.86%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
31.66%
EBIT Growth (5y)
12.96%
EBIT to Interest (avg)
1.93
Debt to EBITDA (avg)
5.29
Net Debt to Equity (avg)
0.42
Sales to Capital Employed (avg)
0.95
Tax Ratio
27.80%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.02%
ROE (avg)
3.13%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
31
Industry P/E
40
Price to Book Value
1.79
EV to EBIT
19.43
EV to EBITDA
15.70
EV to Capital Employed
1.55
EV to Sales
1.16
PEG Ratio
0.11
Dividend Yield
NA
ROCE (Latest)
8.00%
ROE (Latest)
5.83%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

30What is working for the Company
NET SALES(Q)

At Rs 20.81 cr has Grown at 102.43%

PBT LESS OI(Q)

At Rs 1.51 cr has Grown at 459.26%

PAT(Latest six months)

Higher at Rs 2.21 cr

ROCE(HY)

Highest at 7.94%

PBDIT(Q)

Highest at Rs 2.42 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 11.63%

-2What is not working for the Company
OPERATING CF(Y)

Lowest at Rs -6.22 Cr

Loading Valuation Snapshot...
Here's what is working for Concord Drugs
Profit After Tax (PAT) - Latest six months
At Rs 2.21 cr has Grown at 612.90%
Year on Year (YoY)
MOJO Watch
PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
At Rs 20.81 cr has Grown at 102.43%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 1.51 cr has Grown at 459.26%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Latest six months
Higher at Rs 2.21 cr
than preceding 12 month period ended Sep 2026 of Rs 1.06 cr
MOJO Watch
In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 2.42 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 11.63%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Here's what is not working for Concord Drugs
Operating Cash Flow - Annually
Lowest at Rs -6.22 Cr
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (Rs Cr)